Hermann Einsele
Einsele, Hermann 1958-
Einsele, Hermann
Einsele, Herrmann
VIAF ID: 15874714 (Personal)
Permalink: http://viaf.org/viaf/15874714
Preferred Forms
- 100 1 _ ‡a Einsele, Hermann
-
-
- 100 1 _ ‡a Einsele, Hermann ‡d 1958-
-
- 100 0 _ ‡a Hermann Einsele
4xx's: Alternate Name Forms (8)
5xx's: Related Names (5)
- 500 1 _ ‡a Einsele, Gerhard ‡d 1925-2010 ‡4 bezf ‡4 https://d-nb.info/standards/elementset/gnd#familialRelationship ‡e Beziehung familiaer
- 510 2 _ ‡a Medizinische Klinik und Poliklinik ‡g Würzburg, 2 ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 551 _ _ ‡a Stuttgart ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 551 _ _ ‡a Tübingen ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Universitätsklinikum Tübingen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde | |
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life | |
Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten Beiträge zur Gestaltung einer herausfordernden Praxis | |
Cardiovascular adverse events in modern myeloma therapy – incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) | |
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network | |
CXCR4-targeted theranostics in hematooncology: opportunities and challenges = CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen | |
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV | |
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study | |
The EBMT/EHA CAR-T cell handbook | |
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns | |
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) | |
Herausforderungen in der Onkologie - personalisierte Therapiesteuerung virtuelle DGHO Frühjahrstagung 2023 : 22. Maärz 2023, 29. März 2023, 26. April 2023 | |
human leukocyte antigen-DPB1 degree of compatibility is determined by its expression level and mismatch permissiveness: a german multicenter analysis | |
Identification of novel canonical and cryptic HCMV-specific T-cell epitopes for HLA-A*03 and HLA-B*15 via peptide-PRISM | |
Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM | |
Klinische Studien in der Hämatologie und Onkologie | |
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis | |
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) | |
Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host | |
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) | |
The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma | |
PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform. | |
Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. | |
Polymerase Chain Reaction Detection ofAspergillusDNA in Experimental Models of Invasive Aspergillosis | |
Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation | |
Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy. | |
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma | |
Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585. | |
Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement. | |
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. | |
Proteomic Profiling of Serological Responses to Aspergillus fumigatus Antigens in Patients with Invasive Aspergillosis | |
Quantification of T-cell receptor excision circle DNA using fluorescence resonance energy transfer and the LightCycler system | |
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer | |
Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants | |
Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma | |
Real-time PCR and quantitative culture for monitoring of experimental Aspergillus fumigatus intracranial infection in neutropenic mice. | |
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network | |
Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma | |
Robust 8-color flow cytometry panel reveals enhanced effector function of NKG2C+ CD57+ FcεRγ- NK cells in CMV seropositive human blood donors | |
Role of glycogen synthase kinase 3 (GSK-3) in innate immune response of human immature dendritic cells to Aspergillus fumigatus | |
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective | |
Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease | |
Significance of the "halo" sign for progression and regression of nodular pulmonary amyloidosis: radiographic-pathological correlation (2005:6b). | |
Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies | |
Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality | |
Silencing of Dicer1 temporally separates pro- and anti-apoptotic signaling and confers susceptibility to chemotherapy in p53 mutated cells | |
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. | |
Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment. | |
Specific and Novel microRNAs Are Regulated as Response to Fungal Infection in Human Dendritic Cells | |
Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development | |
Specific infectious complications after stem cell transplantation | |
Sporadic late onset nemaline myopathy and immunoglobulin deposition disease. | |
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial | |
State of the art therapy in multiple myeloma and future perspectives | |
Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells | |
Surface display of Gaussia princeps luciferase allows sensitive fungal pathogen detection during cutaneous aspergillosis. | |
Susceptibility of A. fumigatus specific T-cell assays to pre-analytic blood storage and PBMC cryopreservation greatly depends on readout platform and analytes. | |
T-cell therapy for cytomegalovirus infection | |
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease. | |
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. | |
Targeting B-cell non Hodgkin lymphoma: New and old tricks | |
Targeting of the WT191-138 fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination. | |
The temporal dynamics of differential gene expression in Aspergillus fumigatus interacting with human immature dendritic cells in vitro | |
Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy | |
TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation | |
Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors | |
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. | |
Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). | |
Tumor necrosis factor induces tumor promoting and anti-tumoral effects on pancreatic cancer via TNFR1. | |
Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis | |
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody | |
Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. | |
Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. | |
Variant signaling topology at the cancer cell-T-cell interface induced by a two-component T-cell engager | |
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study |